Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 2826 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
 


 

 
     
    Advanced search
 

 
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Email Alert *
    Add to My List *
* Registration required (free)  


    References

 Article Access Statistics
    Viewed342    
    Printed4    
    Emailed0    
    PDF Downloaded70    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
GUEST EDITORIAL  
Year : 2020  |  Volume : 62  |  Issue : 2  |  Page : 112-113
Gender differences: The new challenge for the next years


1 Department of Psychiatry, University Hospital Cochin, Paris University, INSERM U1266, Institute of Psychiatry and Neurosciences, Paris, France
2 Department of Psychiatry, Deva Institute of Healthcare and Research, Varanasi, Uttar Pradesh, India

Click here for correspondence address and email

Date of Submission30-Jan-2020
Date of Acceptance30-Jan-2020
Date of Web Publication17-Mar-2020
 

How to cite this article:
Thibaut F, Jhanwar VG. Gender differences: The new challenge for the next years. Indian J Psychiatry 2020;62:112-3

How to cite this URL:
Thibaut F, Jhanwar VG. Gender differences: The new challenge for the next years. Indian J Psychiatry [serial online] 2020 [cited 2020 Apr 4];62:112-3. Available from: http://www.indianjpsychiatry.org/text.asp?2020/62/2/112/280875




The prevalence, age at onset, and clinical symptoms of many neuropsychiatric diseases substantially differ between males and females. Examples of female-biased conditions include emotional disorders such as depression, anxiety disorder, or anorexia nervosa, which usually starts around puberty or later in life; examples of male-biased conditions include early-onset disorders that involve a certain degree of neurodevelopmental impairment, such as autism, attention deficit/hyperactivity disorder, conduct disorder, specific language impairment, and Tourette syndrome or schizophrenia.[1] Factors influencing the relationships between brain development and function and sex/gender may help to understand the differences between males and females in terms of risk or resilience factors to brain diseases. Epigenetic modifications involving DNA methylation and histone deacetylation are also essential for feminization or masculinization of sexual behavior.[2],[3] Unfortunately, in preclinical research, in most cases, researchers do not use female animals and consider that there are no sex differences in brain function outside of reproductive behavior. Single sex studies of male animals outnumber those of females: 5.5–1.3. In addition, clinical studies conducted in both sexes frequently forget to analyze results by sex/gender.[4],[5]

The mean rate of depressive disorders for females is approximately twice that of males (1.63–3.89)[6],[7] (and almost 3 times higher in South Asia, including India). Most of anxiety disorders are more common in women than men (2–3 fold increase in the occurrence of generalized anxiety disorder and panic disorder; social anxiety disorder is also more frequent in women with an odds ratio of 1.2–1.5). Anxiety disorders are more likely to be chronic, often complicated by other comorbid psychiatric disorders, and associated with more functional impairment in women.[8] Concerning schizophrenia, the male/female incidence approximates 1.4/1 but after 50-year-old women predominate; the functional outcome is usually better in women.[9] Finally, the prevalence of dependence or harmful use of alcohol and the prevalence of tobacco or illicit drug use are generally higher in adult men. However, epidemiological studies indicate an alarming narrowing in this gender gap, especially in adolescents. These behavioral changes may reflect changes in sociocultural patterns rather than biology. In fact, women are gradually losing the protection they had from historic social roles. In most countries, the mean level of alcohol use has gradually decreased over time, but in some countries such as India, China, Russia, some Latin American countries, and Eastern Europe, the mean consumption has increased from 2000 to 2013 (https://dx.doi.org/10.1787/health-data-fr). Health consequences significantly differ according to sex/gender. There are also important gender differences in terms of pharmacokinetics and pharmacodynamics. For example, the World Health Organization has defined different risks for occasional and chronic alcohol use, which are significantly lower in women: low risk (<20 g/day), moderate risk (>20–40 g/day), and high risk (>40 g/day). There is no safe level for tobacco or illicit drug use. Cardiovascular diseases are the most important cause of alcohol-attributable mortality in women. The risk of breast cancer increases according to the daily dose of alcohol use with a relative risk (RR) of 5–9 with one standard drink daily and of 41 with 3–6 standard drinks daily.[10] The protective cardiovascular effect of alcohol at low dose is less clear in women compared with men, in whom a clear decrease in RR of ischemic heart disease is observed at doses lower than 2–3 standard drinks daily. In the US, Jemal et al.[11] have reported an important decrease in annual age-adjusted death rates from almost all cancers among females (including breast cancer) except for lung and bronchus cancer, which has dramatically increased since the 1930s. These findings were confirmed by Pirie et al.[12] in a cohort of 1.2 million women followed for 12 years in the UK. In addition, heavy drinking puts women at risk of injuries and death from accidents, as well as unsafe sex, sexual assaults, and violence. Yet, the small number of studies on gender differences in addiction is surprising when considering the modulatory role of estradiol in decision-making and its interplay with dopamine in modulating reward, motivation, and cognitive processes. Men and women are also differentially affected by environmental triggers for relapse to drug-taking. As compared to men, women use more often psychoactive substances to cope with stress and negative feelings. Women are also more likely to have a lower socioeconomic status, which might also be a risk factor for addictive disorders. Potenza et al.[13] reported sex differences in the neural correlates of cocaine-induced craving. Corticostriatal-limbic hyperactivity was linked to stress cues in women but to drug cues in men. In the same way, women are also less sensitive to the reinforcing effects of nicotine but more sensitive to social cues. Young women are seen everywhere by the alcohol and tobacco industry as a potential growth market.

Finally, women's consumption of tobacco, alcohol, or illicit substances during pregnancy may be associated with serious birth and developmental consequences in newborns. Despite the international consensus recommending total abstinence of psychoactive drug use during pregnancy, prenatal alcohol, tobacco, or illicit drug exposure remains a major public health issue. In particular, alcohol consumption during pregnancy is associated with a large range of adverse effects including spontaneous abortion, stillbirth, weight and growth deficiencies, birth defects, prematurity, and fetal alcohol spectrum disorder. On the basis of data obtained in seven countries (Australia, Canada, Croatia, France, Italy, South Korea, and the US) on the prevalence of both alcohol use during pregnancy and resulting fetal alcohol syndrome (FAS), Popova et al.[14] estimated that one in every 67 mothers who consumed alcohol during pregnancy gave birth to a child with FAS. Prematurity and low birth weight are also frequently associated with tobacco exposure during pregnancy (smoking or secondhand smoke). The International Association of Women's Mental Health and the World Federation of Societies of Biological Psychiatry have recently published guidelines for the management of alcohol use during pregnancy.[15]

Female outpatients are still underrepresented in specialized treatment settings, particularly for the treatment of addictive disorders. Training care providers in primary care and mental health settings may help to identify and refer women to psychiatry and specialty addiction services. Providing services, such as child care, also help keeping women in treatment. Finally, raising public awareness about the risks of alcohol, tobacco, and illicit drug use during pregnancy is crucial, especially in all women of childbearing age.



 
   References Top

1.
Wickens MM, Bangasser DA, Briand LA. Sex Differences in Psychiatric Disease: A Focus on the Glutamate System. Front Mol Neurosci 2018;11:197.  Back to cited text no. 1
    
2.
Nugent BM, Wright CL, Shetty AC, Hodes GE, Lenz KM, Mahurkar A, et al. Brain feminization requires active repression of masculinization via DNA methylation. Nat Neurosci 2015;18:690-7.  Back to cited text no. 2
    
3.
Bale TL, Epperson CN. Sex differences and stress across the lifespan. Nat Neurosci 2015;18:1413-20.  Back to cited text no. 3
    
4.
Thibaut F. The role of sex and gender in neuropsychiatric disorders. Dialogues Clin Neurosci 2016;18:351-2.  Back to cited text no. 4
    
5.
Thibaut F. Gender does matter in clinical research. Eur Arch Psychiatry Clin Neurosci 2017;267:283-4.  Back to cited text no. 5
    
6.
World Health Organization. Department of Mental Health and Substance Dependence. Gender Disparities in Mental Health. Geneva: World Health Organization; 2013.  Back to cited text no. 6
    
7.
Yu S. Uncovering the hidden impacts of inequality on mental health: A global study. Transl Psychiatry 2018;8:98.  Back to cited text no. 7
    
8.
Jalnapurkar I, Allen M, Pigott T. Sex differences in anxiety disorders: A review. Psychiatr Depress Anxiety 2018;4:12.  Back to cited text no. 8
    
9.
Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. Int Rev Psychiatry 2010;22:417-28.  Back to cited text no. 9
    
10.
Schütze M, Boeing H, Pischon T, Rehm J, Kehoe T, Gmel G, et al. Alcohol attributable burden of incidence of cancer in eight European countries based on results from prospective cohort study. BMJ 2011;342:d1584.  Back to cited text no. 10
    
11.
Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008;100:1672-94.  Back to cited text no. 11
    
12.
Pirie K, Peto R, Reeves GK, Green J, Beral V; Million Women Study Collaborators. The 21st century hazards of smoking and benefits of stopping: A prospective study of one million women in the UK. Lancet 2013;381:133-41.  Back to cited text no. 12
    
13.
Potenza MN, Hong KI, Lacadie CM, Fulbright RK, Tuit KL, Sinha R. Neural correlates of stress-induced and cue-induced drug craving: Influences of sex and cocaine dependence. Am J Psychiatry 2012;169:406-14.  Back to cited text no. 13
    
14.
Popova S, Lange S, Probst C, Gmel G, Rehm J. Estimation of national, regional, and global prevalence of alcohol use during pregnancy and fetal alcohol syndrome: A systematic review and meta-analysis. Lancet Glob Health 2017;5:e290-e299.  Back to cited text no. 14
    
15.
Thibaut F, Chagraoui A, Buckley L, Gressier F, Labad J, Lamy S, et al. World Federation of Societies of Biological Psychiatry and International Association for Women's Mental Health Guidelines for the treatment of Alcohol Use Disorders in pregnant women. World J Biol Psychiatry 2019;20:17-50. [Doi: 10.1080/15622975.2018.1510185].  Back to cited text no. 15
    

Top
Correspondence Address:
Prof. Florence Thibaut
University Hospital Cochin, Paris University, INSERM U1266, Institute of Psychiatry and Neurosciences, Paris
France
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/psychiatry.IndianJPsychiatry_75_20

Rights and Permissions




 

Top